Yokogawa is enabling innovation and digitalization of Europe’s pharmaceutical industry; ensuring stable and reliable supply of medicines to patients.
Pharmaceutical companies must achieve:
- increased flexibility and agility through better use and monitoring of manufacturing data to improve quality management in real time
- reduced time to market
- increased process efficiency.
Improve quality management in real time
Reduced time to market
Increased process efficiency
Right first-time, and zero-waste drug manufacturing are enabled by the utilization and smart analysis of manufacturing data in real-time.
With Yokogawa products and services, we safely, securely and smartly enable higher production flexibility, quicker and more agile process implementation, improved supply chain management, and faster achievement of target yields.
Deployed on-premise, in the cloud and at the edge, our technology and know-how deliver improvement in production quality, flexibility and cost.
Yokogawa … Integrator of all; ensuring well-being of all.
Do you want to be informed of Yokogawa’s latest perspectives and innovations in the Pharma Industry?
Pharmaceutical
The pharmaceutical industry currently faces a major challenge in taking full advantage of the opportunities presented in large emerging markets. Now, more than ever, pharmaceutical companies need to introduce lean manufacturing techniques that will enhance profitability. As one of the world's leading industrial automation suppliers, Yokogawa is committed to delivering the best possible solutions for your best manufacturing practices.
Publikationen
A critical requirement in biopharmaceutical development is the integration and automation of process equipment and analytical instruments used in the laboratory. Bioprocess labs with multiple lab-scale bioreactors often execute cultivation experiments in parallel for research or process development purposes.
As part of a collaboration between Securecell (Zurich, SW) and Yokogawa Life Science (Tokyo, Japan), this application note demonstrates the effective use of the Lucullus® Process Information Management System (Lucullus®) to assist in the control of three Advanced Control Bioreactor Systems (BR1000) to study glucose utilization of CHO cells for optimal monoclonal antibody productivity.
The critical steps in achieving advanced process control include building an accurate digital twin of a bioreactor, validating it, and establishing communication between the bioreactor and its digital twin. Several of these steps are already mature and Yokogawa is making rapid progress toward realizing ‘smart’ bioreactors for smart manufacturing.
Yokogawa Insilico Biotechnology released its Insilico Digital Twin Factory, which can help drugmakers increase productivity and bring down manufacturing costs and time to market by potentially replacing up to 50% of the experiments needed during the process development, characterization and scale-up of biopharmaceuticals.
Downloads
Zertifikate
Videos
Welcome to a transformative journey in the pharmaceutical industry!
News
-
Pressemeldung Feb 15, 2023 Echtzeit-Überwachung von Polymeren und Biopolymeren: Yokogawa übernimmt Fluence Analytics
Fluence Analytics zählt zu den Weltmarktführern bei der Überwachung und Steuerung von Polymerisationsreaktionen. Sein Produkt „Automatic Continuous Online Monitoring of Polymerizations“ ist das einzige System am Markt, das mehrere Polymereigenschaften in Echtzeit messen und analysieren kann. Durch die Übernahme wird Fluence Analytics seine Aktivitäten in das bestehende Geschäft von Yokogawa integrieren und seine technologischen Kapazitäten weiter ausbauen.
-
Pressemeldung Nov 10, 2021 Yokogawa erwirbt mit Insilico Biotechnology einen Entwickler von Digital Twin-basierter Technologie für Bioprozesse
Yokogawa erwirbt mit Insilico Biotechnology einen Entwickler von Digital Twin-basierter Technologie für Bioprozesse. Die Insilico Biotechnology AG ist ein in Stuttgart ansässiger Anbieter von Bioprozesssoftware und -dienstleistungen.
-
Pressemeldung Dez 3, 2020 Unterstützung der Forschung zur Arzneimittelentwicklung: Yokogawa und InSphero schließen Partnerschaftsabkommen
- Das Biotechnologieunternehmen InSphero AG ist Pionier in der Entwicklung von 3D-in-vitro-Technologien für die Arzneimittelentwicklung. Die Yokogawa Electric Corporation und die InSphero AG haben eine Partnerschaft vereinbart, um Methoden für den Einsatz der High-Content-Analyse1 (HCA) in der Arzneimittelforschung und -sicherheitsbewertung zu etablieren und weiterzuentwickeln.-
-
Pressemeldung Okt 5, 2021 Yokogawa UK and Source Medical announce partnership for societal well-being
Source Medical, a leading provider of turnkey healthcare solutions and Yokogawa UK, announce a partnership that combines best in class technology and services to co-create value for the well-being of society through collaborative activities in the healthcare industry.
-
Pressemeldung Mr 1, 2023 KI-gestützte Viewport-Software weltweit: Yokogawa schließt Partnerschaft mit der Radial Software Group
Die von Viewport bereitgestellten KI-gestützten Lösungen erweitern die Leistungsfähigkeit des Asset Managements. Indem die Plattform einen zentralen Überblick über alle veröffentlichten technischen Informationen bereitstellt, werden Risiken reduziert, und die Operational Excellence steigt. Die Yokogawa Electric Corporation wird als globaler Value Added Reseller für die Viewport-Software der Radial Software Group fungieren.
Möchten Sie weitere Informationen über unsere Mitarbeiter, Technologien und Lösungen?
Kontakt